Celgene licenses MorphoSys antibody for up to $818m
This article was originally published in Scrip
Executive Summary
Celgene agreed to pay up to $818 million plus royalties to license and jointly develop the fully human monoclonal antibody MOR202 developed by MorphoSys to target CD38 for the treatment of multiple myeloma and certain leukemias.